Navigation Links
Coria Laboratories Announces Acanya(TM) Gel Data Presentations at 67th American Academy of Dermatology Annual Meeting
Date:2/26/2009

FORT WORTH, Texas, Feb. 26 /PRNewswire-FirstCall/ -- Coria Laboratories, the newly expanded dermatology division of Valeant Pharmaceuticals International (NYSE: VRX), today announced six data presentations on Acanya Gel at the 67th Annual Meeting of the American Academy of Dermatology (AAD), taking place March 6 - 10, 2009, at the Moscone Center, San Francisco. The presentations demonstrate the efficacy and safety of once daily Acanya Gel (clindamycin phosphate 1.2% and benzoyl peroxide 2.5%) in treating patients with moderate to severe acne vulgaris.

"Data to be presented at AAD will confirm the superior efficacy of Acanya Gel over active ingredients and vehicle for both inflammatory and non-inflammatory acne lesions, while showing favorable safety and tolerability in patients with moderate to severe acne vulgaris," said Steve Clark, president of Coria Laboratories. "Other highlights include a presentation on how Acanya Gel was developed to enhance the bioavailability of benzoyl peroxide while minimizing the risk of skin irritation, a discussion on Acanya Gel's role in effective management of adolescent acne, and a session on the importance of Patient Reported Outcomes in the treatment of acne vulgaris."

Following are details for each poster presentation. (All times are Pacific Standard Time. All presentations are located in Moscone Center North, Hall E)

Friday, March 6, 2009, 11:20 a.m.

Abstract #717

Poster Discussion: Can delivery be enhanced and skin irritation minimized using a lower concentration of benzoyl peroxide in a fixed combination product?

Presenter: Jim Del Rosso, D.O., Las Vegas Skin & Cancer Clinic, Las Vegas, Nevada

Friday, March 6, 2009, 11:30 a.m.

Abstract #718

Poster Discussion: Assessing efficacy of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in the treatment of severe acne

Presenter: Michael Gold, M.D., Tennessee Clinical Research Center, Nashville, Tennessee

Friday, March 6, 2009, 12:30 p.m.

Abstract #724

Poster Discussion: Patient reported outcomes using a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the treatment of moderate to severe acne in 2,813 subjects

Presenter: Jonathan Weiss, M.D., Gwinnett Clinical Research Center, Snellville, Georgia

Friday, March 6, 2009, 2:50 p.m.

Abstract #738

Poster Discussion: Efficacy of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate to severe acne

Presenter: Diane Thiboutot, M.D., Department of Dermatology, the Pennsylvania State University College of Medicine, Hershey, Pennsylvania

Friday, March 6, 2009, 3:00 p.m.

Abstract #739

Poster Discussion: Safety and cutaneous tolerability of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel for the once-daily treatment of moderate to severe acne

Presenter: Diane Thiboutot, M.D., Department of Dermatology, the Pennsylvania State University College of Medicine, Hershey

Friday, March 6, 2009, 3:10 p.m.

Abstract #740

Poster Discussion: Managing moderate to severe acne in adolescents: Benefits of a fixed combination clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in a subpopulation of 1,755 subjects

Presenter: Lawrence Eichenfield, M.D., Department of Dermatology, University of California, San Diego School of Medicine, San Diego, California

About Acanya Gel

Acanya Gel is the only FDA-approved fixed combination antibiotic and benzoyl peroxide (BPO) medication for once-daily treatment of both non-inflammatory and inflammatory lesions of acne. Formulated in an aqueous-based, alcohol-free gel, Acanya Gel was optimized to provide enhanced bioavailability of BPO, creating an effective and well tolerated product. In pivotal Phase III clinical trials, Acanya Gel showed superior efficacy to the vehicle gel and either individual active ingredient, while demonstrating excellent tolerability and very high patient satisfaction scores.

Acanya Gel was developed by Arcutis Pharmaceuticals, now a part of Coria Laboratories, a division of Valeant Pharmaceuticals International. Acanya Gel is protected by two U.S. Patents and has pending patent applications. More information about Acanya Gel can be obtained at http://www.AcanyaGel.com.

Indication and Important Safety Information for Acanya Gel

Acanya Gel (clindamycin phosphate 1.2% and benzoyl peroxide 2.5%) is indicated for the topical treatment of acne vulgaris in patients 12 years of age or older. In controlled clinical trials, the following application-site adverse reactions occurred in less than 0.2% of patients treated with Acanya Gel: application-site pain (0.1%), application-site exfoliation (0.1%), and application-site irritation (0.1%). Patients are advised to avoid applying in mouth, eyes, or nose or on lips, and to minimize sun exposure following the application of Acanya Gel.

About Coria Laboratories

Coria Laboratories is the dermatology division of Valeant Pharmaceuticals International. With its acquisition of Coria Laboratories Ltd. in October 2008, Valeant has created a fully integrated portfolio of specialty pharmaceutical products focused on medical dermatology. Coria Laboratories combines a commercial organization with management expertise, a proven sales force and a goal of developing and marketing innovative products, positioning Coria Laboratories for dermatology industry leadership going forward. Coria Laboratories is committed to establishing a tradition of unparalleled service to the dermatology community, with the critical goal of supporting dermatologists and their practices through greater patient satisfaction with therapy. For more information, please visit http://www.corialabs.com.

About Valeant Pharmaceuticals:

Valeant Pharmaceuticals International (NYSE: VRX) is a multinational specialty pharmaceutical company that develops and markets a broad range of pharmaceutical products primarily in the areas of neurology and dermatology. More information about Valeant can be found at http://www.valeant.com.

FORWARD-LOOKING STATEMENTS:

This press release contains forward-looking statements, including, but not limited to, statements regarding the efficacy of Acanya and favorable safety profile. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to the data to be presented at AAD that will confirm the superior efficacy of Acanya Gel and other risks and uncertainties discussed in the company's annual report or Form 10-K for the years ended December 31, 2007 and other filings with the SEC. Valeant wishes to caution the reader that these factors are among the factors that could cause actual results to differ materially from the expectations described in the forward-looking statements. Valeant also cautions the reader that undue reliance should not be placed on any of the forward-looking statements, which speak only as of the date of this release. The company undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this release or to reflect actual outcomes.

    (Logo:http://www.newscom.com/cgi-bin/prnh/20081125/VALEANTLOGO)

     Contacts:
     Investors:                         Media:
     Laurie W. Little                   Carole Melis
     949-461-6002                       650-342-5686
     laurie.little@valeant.com          clmcomm1@gmail.com

'/>"/>
SOURCE Valeant Pharmaceuticals International
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
2. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
3. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
5. Sandia National Laboratories Selects Allscripts Electronic Health Record and Practice Management for Employee Health Center
6. Andrew Lessmans TWC Construction and ProCaps Laboratories Contract With DT Solar to Install a 700 kW Solar Electric System
7. Mesa Laboratories Names New Vice President of Sales and Marketing
8. Caraco Pharmaceutical Laboratories Ltd. Announces Tentative FDA Approval for Generic Zyrtec Chewable(R)
9. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2008 Second Quarter Earnings
10. Roxane Laboratories, Inc. Announces the Launch of Oxcarbazepine Tablets, 150mg, 300mg and 600mg
11. JDRF partners with Housey Pharmaceutical Research Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... Washington, DC (PRWEB) , ... July 26, 2017 ... ... Arise Infusion is pleased to now offer a major advancement in drug therapy ... their lives. Ocrevus (pronounced Ah-creh-vus) is a novel B cell targeted therapy ...
(Date:7/26/2017)... Yorba Linda, Ca (PRWEB) , ... July 26, 2017 , ... ... of optimize lyophilization processes. Inconsistent results freeze drying samples and a lengthy freeze dry ... , This webinar will discuss freeze drying techniques, as well as new accessories and ...
(Date:7/26/2017)... ... July 26, 2017 , ... ... host its 2017 Process Validation and Process Validation Statistics Conferences in Bethesda, ... process validation lifecycle challenges faced by process validation professionals and statisticians today. ...
(Date:7/26/2017)... ... ... Team Type 1 Foundation, a nonprofit organization pursuing a global mission of education, ... announce the 106 college athletes with type 1 diabetes who will receive scholarships as ... 1 Foundation has bestowed a total of 271 college scholarships to athletes with type ...
(Date:7/26/2017)... ... July 26, 2017 , ... IDC-Eating Disorder Care ... the treatment program located in Royal Oak, Michigan. IDC, formerly known as ... focused on providing the highest standards in the field of eating disorder treatment in ...
Breaking Medicine News(10 mins):
(Date:7/14/2017)... , July 13, 2017 It should come ... States is in the midst of a crippling ... , since 1999, the number of overdose deaths from opiate-based ... in over half a million dead from 2001 to 2015". ... oxycodone, and hydrocodone has similarly quadrupled, drawing a compelling link ...
(Date:7/12/2017)... , July 12, 2017  Eli Lilly and Company (NYSE: ... with generic companies to resolve pending patent litigation in the ... Virginia regarding the Cialis ® (tadalafil) unit ... April 26, 2020. As part of the agreement, Cialis exclusivity ... 27, 2018. "The unit dose patent for Cialis ...
(Date:7/11/2017)... SARASOTA, Fla. , July 11, 2017  Dr. Echenberg, founder of ... Dilator therapy program to patients who suffer from painful intercourse and other ... vaginismus and vaginal atrophy due to menopause. ... VuVatech LLC ... Dilators , created by Sarasota, Florida -based start-up company, ...
Breaking Medicine Technology: